Mechanisms of FGFR-mediated carcinogenesis

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1823, Issue 4, 2012, Pages 850-860

  Ahmad, Imran ^a,b   Iwata, Tomoko ^b   Leung, Hing Y ^a,b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer; Cancer therapy; FGF; FGFR; Receptor tyrosine kinase; Signalling

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; ANTINEOPLASTIC AGENT; AZD 4547; BGJ 398; DOVITINIB; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FP 1039; GP 369; PHOSPHOLIPASE C GAMMA; R3MAB ANTIBODY; RECOMBINANT KERATINOCYTE GROWTH FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ANTIPROLIFERATIVE ACTIVITY; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER GROWTH; CANCER RELAPSE; CARCINOGENESIS; CHROMOSOME TRANSLOCATION; ENDOMETRIUM CANCER; GENE AMPLIFICATION; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR UPREGULATION; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SOMATIC MUTATION; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLAST GROWTH FACTORS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84857433085     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2012.01.004     Document Type: Review

References (181)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
2. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
3. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
4. Haugsten E.M., Wiedlocha A., Olsnes S., Wesche J.r. Roles of fibroblast growth factor receptors in carcinogenesis. Mol. Cancer Res. 2010, 8:1439-1452.
5. Kimelman D., Kirschner M. Synergistic induction of mesoderm by FGF and TGF-[beta] and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell 1987, 51:869-877.
6. De Moerlooze L., Spencer-Dene B., Revest J., Hajihosseini M., Rosewell I., Dickson C. An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis. Development 2000, 127:483-492.
7. Dillon C., Spencer-Dene B., Dickson C. A crucial role for fibroblast growth factor signaling in embryonic mammary gland development. J. Mammary Gland Biol. Neoplasia 2004, 9:207-215.
8. Gospodarowicz D., Bialecki H., Greenburg G. Purification of the fibroblast growth factor activity from bovine brain. J. Biol. Chem. 1978, 253:3736-3743.
9. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
10. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., Gerard R.D., Repa J.J., Mangelsdorf D.J., Kliewer S.A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-225.
11. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., Sandusky G.E., Hammond L.J., Moyers J.S., Owens R.A., Gromada J., Brozinick J.T., Hawkins E.D., Wroblewski V.J., Li D.S., Mehrbod F., Jaskunas S.R., Shanafelt A.B. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
12. Riminucci M., Collins M.T., Fedarko N.S., Cherman N., Corsi A., White K.E., Waguespack S., Gupta A., Hannon T., Econs M.J., Bianco P., Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 2003, 112:683-692.
13. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001, 60:2079-2086.
14. Yu X., White K.E. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 2005, 16:221-232.
15. Ezzat S., Asa S.L. FGF receptor signaling at the crossroads of endocrine homeostasis and tumorigenesis. Horm. Metab. Res. 2005, 37:355-360.
16. Bryant D.M., Stow J.L. Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic 2005, 6:947-954.
17. Grose R., Dickson C. Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev. 2005, 16:179-186.
18. Ori A., Wilkinson M.C., Fernig D.G. The heparanome and regulation of cell function: structures, functions and challenges. Front. Biosci. 2008, 13:4309-4338.
19. Harmer N.J., Ilag L.L., Mulloy B., Pellegrini L., Robinson C.V., Blundell T.L. Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex. J. Mol. Biol. 2004, 339:821-834.
20. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005, 16:107-137.
21. Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F., Gao G., Goldfarb M. Receptor specificity of the fibroblast growth-factor family. J. Biol. Chem. 1996, 271:15292-15297.
22. Ornitz D.M., Itoh N. Fibroblast growth factors. Genome Biol. 2001, 2. (3005-3005.3012).
23. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 2006, 281:15694-15700.
24. Johnson D.E., Williams L.T. Structural and functional diversity in the FGF receptor multigene family. Adv. Cancer Res. 1993, 60:1-41.
25. Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A., Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M. Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:935-940.
26. Zhang X. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 2006, 281:15694-15700.
27. Knights V., Cook S.J. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol. Ther. 2010, 125:105-117.
28. Mohammadi M., Honegger A.M., Rotin D., Fischer R., Bellot F., Li W., Dionne C.A., Jaye M., Rubinstein M., Schlessinger J. A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1. Mol. Cell. Biol. 1991, 11:5068-5078.
29. Mohammadi M., Dikic I., Sorokin A., Burgess W.H., Jaye M., Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol. Cell. Biol. 1996, 16:977-989.
30. Furdui C.M., Lew E.D., Schlessinger J., Anderson K.S. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction. Mol. Cell 2006, 21:711-717.
31. Lew E.D., Furdui C.M., Anderson K.S., Schlessinger J. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci. Signal. 2009, 2:ra6.
32. Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M., Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M. A crystallographic snapshot of tyrosine trans-phosphorylation in action. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19660-19665.
33. Powers C.J., McLeskey S.W., Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr. Relat. Cancer 2000, 7:165-197.
34. Rand V., Huang J., Stockwell T., Ferriera S., Buzko O., Levy S., Busam D., Li K., Edwards J.B., Eberhart C., Murphy K.M., Tsiamouri A., Beeson K., Simpson A.J., Venter J.C., Riggins G.J., Strausberg R.L. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14344-14349.
35. Cross N.C., Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002, 16:1207-1212.
36. Gotoh N. Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins. Cancer Sci. 2008, 99:1319-1325.
37. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
38. Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., Donoghue D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19:3309-3320.
39. Kang S., Elf S., Dong S., Hitosugi T., Lythgoe K., Guo A., Ruan H., Lonial S., Khoury H.J., Williams I.R., Lee B.H., Roesel J.L., Karsenty G., Hanauer A., Taunton J., Boggon T.J., Gu T.L., Chen J. Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol. Cell. Biol. 2009, 29:2105-2117.
40. Zhao Y., Zhang Z.Y. The mechanism of dephosphorylation of extracellular signal-regulated kinase 2 by mitogen-activated protein kinase phosphatase 3. J. Biol. Chem. 2001, 276:32382-32391.
41. Casci T., Vinos J., Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell 1999, 96:655-665.
42. Hacohen N., Kramer S., Sutherland D., Hiromi Y., Krasnow M.A. Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 1998, 92:253-263.
43. Furthauer M., Lin W., Ang S.L., Thisse B., Thisse C. Sef is a feedback-induced antagonist of Ras/MAPK-mediated FGF signalling. Nat. Cell Biol. 2002, 4:170-174.
44. Tsang M., Friesel R., Kudoh T., Dawid I.B. Identification of Sef, a novel modulator of FGF signalling. Nat. Cell Biol. 2002, 4:165-169.
45. Tsang M., Dawid I.B. Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. Sci. STKE 2004, 228:7.
46. Thien C.B., Langdon W.Y. Cbl: many adaptations to regulate protein tyrosine kinases. Nat. Rev. Mol. Cell Biol. 2001, 2:294-307.
47. Haugsten E.M., Malecki J., Bjorklund S.M., Olsnes S., Wesche J. Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis. Mol. Biol. Cell 2008, 19:3390-3403.
48. Yagasaki F., Wakao D., Yokoyama Y., Uchida Y., Murohashi I., Kayano H., Taniwaki M., Matsuda A., Bessho M. Fusion of ETV6 to fibroblast growth factor receptor 3 in peripheral T-cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation. Cancer Res. 2001, 61:8371-8374.
49. Roumiantsev S., Krause D.S., Neumann C.A., Dimitri C.A., Asiedu F., Cross N.C., Van Etten R.A. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell 2004, 5:287-298.
50. Xiao S., Nalabolu S.R., Aster J.C., Ma J., Abruzzo L., Jaffe E.S., Stone R., Weissman S.M., Hudson T.J., Fletcher J.A. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome. Nat. Genet. 1998, 18:84-87.
51. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum. Pathol. 2010, 41:461-476.
52. Demiroglu A., Steer E.J., Heath C., Taylor K., Bentley M., Allen S.L., Koduru P., Brody J.P., Hawson G., Rodwell R., Doody M.L., Carnicero F., Reiter A., Goldman J.M., Melo J.V., Cross N.C. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood 2001, 98:3778-3783.
53. Ren M., Li X., Cowell J.K. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. Blood 2009, 114:1576-1584.
54. Chen J., Deangelo D.J., Kutok J.L., Williams I.R., Lee B.H., Wadleigh M., Duclos N., Cohen S., Adelsperger J., Okabe R., Coburn A., Galinsky I., Huntly B., Cohen P.S., Meyer T., Fabbro D., Roesel J., Banerji L., Griffin J.D., Xiao S., Fletcher J.A., Stone R.M., Gilliland D.G. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14479-14484.
55. Guasch G., Delaval B., Arnoulet C., Xie M.J., Xerri L., Sainty D., Birnbaum D., Pebusque M.J. FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice. Blood 2004, 103:309-312.
56. Chang H., Stewart A.K., Qi X.Y., Li Z.H., Yi Q.L., Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 2005, 106:353-355.
57. Chesi M., Nardini E., Brents L.A., Schröck E., Ried T., Kuehl W.M., Bergsagel P.L. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 1997, 16:260-264.
58. Keats J.J., Reiman T., Belch A.R., Pilarski L.M. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk. Lymphoma 2006, 47:2289-2300.
59. Qing J., Du X., Chen Y., Chan P., Li H., Wu P., Marsters S., Stawicki S., Tien J., Totpal K., Ross S., Stinson S., Dornan D., French D., Wang Q.R., Stephan J.P., Wu Y., Wiesmann C., Ashkenazi A. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 2009, 119:1216-1229.
60. Trudel S., Stewart A.K., Rom E., Wei E., Li Z.H., Kotzer S., Chumakov I., Singer Y., Chang H., Liang S.B., Yayon A. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood 2006, 107:4039-4046.
61. Grand E.K., Chase A.J., Heath C., Rahemtulla A., Cross N.C. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004, 18:962-966.
62. Trudel S., Ely S., Farooqi Y., Affer M., Robbiani D.F., Chesi M., Bergsagel P.L. Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma. Blood 2004, 103:3521-3528.
63. Kwabi-Addo B., Ozen M., Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr. Relat. Cancer 2004, 11:709-724.
64. Freier K., Schwaenen C., Sticht C., Flechtenmacher C., Mühling J., Hofele C., Radlwimmer B., Lichter P., Joos S. Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol. 2007, 43:60-66.
65. Jacquemier J., Adelaide J., Parc P., Penault-Llorca F., Planche J., deLapeyriere O., Birnbaum D. Expression of the FGFR1 gene in human breast-carcinoma cells. Int. J. Cancer 1994, 59:373-378.
66. Meyer K.B., Maia A.T., O'Reilly M., Teschendorff A.E., Chin S.F., Caldas C., Ponder B.A. Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 2008, 6:108.
67. Nakazawa K., Yashiro M., Hirakawa K. Keratinocyte growth factor produced by gastric fibroblasts specifically stimulates proliferation of cancer cells from scirrhous gastric carcinoma. Cancer Res. 2003, 63:8848-8852.
68. Clark J.C., Tichelaar J.W., Wert S.E., Itoh N., Perl A.K., Stahlman M.T., Whitsett J.A. FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L705-L715.
69. Marek L., Ware K.E., Fritzsche A., Hercule P., Helton W.R., Smith J.E., McDermott L.A., Coldren C.D., Nemenoff R.A., Merrick D.T., Helfrich B.A., Bunn P.A., Heasley L.E. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol. Pharmacol. 2009, 75:196-207.
70. van Rhijn B.W., van Tilborg A.A., Lurkin I., Bonaventure J., de Vries A., Thiery J.P., van der Kwast T.H., Zwarthoff E.C., Radvanyi F. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur. J. Hum. Genet. 2002, 10:819-824.
71. Murphy T., Darby S., Mathers M.E., Gnanapragasam V.J. Evidence for distinct alterations in the FGF axis in prostate cancer progression to an aggressive clinical phenotype. J. Pathol. 2010, 220:452-460.
72. Acevedo V.D., Gangula R.D., Freeman K.W., Li R., Zhang Y., Wang F., Ayala G.E., Peterson L.E., Ittmann M., Spencer D.M. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. Cancer Cell 2007, 12:559-571.
73. Jang J.H., Shin K.H., Park J.G. Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 2001, 61:3541-3543.
74. Kunii K., Davis L., Gorenstein J., Hatch H., Yashiro M., Di Bacco A., Elbi C., Lutterbach B. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008, 68:2340-2348.
75. Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J. Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform. J. Biol. Chem. 2009, 284:6227-6240.
76. Chin K., DeVries S., Fridlyand J., Spellman P.T., Roydasgupta R., Kuo W.L., Lapuk A., Neve R.M., Qian Z., Ryder T., Chen F., Feiler H., Tokuyasu T., Kingsley C., Dairkee S., Meng Z., Chew K., Pinkel D., Jain A., Ljung B.M., Esserman L., Albertson D.G., Waldman F.M., Gray J.W. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 2006, 10:529-541.
77. Gelsi-Boyer V., Orsetti B., Cervera N., Finetti P., Sircoulomb F., Rouge C., Lasorsa L., Letessier A., Ginestier C., Monville F., Esteyries S., Adelaide J., Esterni B., Henry C., Ethier S.P., Bibeau F., Mozziconacci M.J., Charafe-Jauffret E., Jacquemier J., Bertucci F., Birnbaum D., Theillet C., Chaffanet M. Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol. Cancer Res. 2005, 3:655-667.
78. Letessier A., Sircoulomb F., Ginestier C., Cervera N., Monville F., Gelsi-Boyer V., Esterni B., Geneix J., Finetti P., Zemmour C., Viens P., Charafe-Jauffret E., Jacquemier J., Birnbaum D., Chaffanet M. Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 2006, 6:245.
79. Bernard-Pierrot I., Gruel N., Stransky N., Vincent-Salomon A., Reyal F., Raynal V., Vallot C., Pierron G., Radvanyi F., Delattre O. Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res. 2008, 68:7165-7175.
80. Garcia M.J., Pole J.C., Chin S.F., Teschendorff A., Naderi A., Ozdag H., Vias M., Kranjac T., Subkhankulova T., Paish C., Ellis I., Brenton J.D., Edwards P.A., Caldas C. A 1Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 2005, 24:5235-5245.
81. Behbod F., Xian W., Shaw C.A., Hilsenbeck S.G., Tsimelzon A., Rosen J.M. Transcriptional profiling of mammary gland side population cells. Stem Cells 2006, 24:1065-1074.
82. Xian W., Pappas L., Pandya D., Selfors L.M., Derksen P.W., de Bruin M., Gray N.S., Jonkers J., Rosen J.M., Brugge J.S. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res. 2009, 69:2244-2251.
83. Xian W., Schwertfeger K.L., Vargo-Gogola T., Rosen J.M. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J. Cell Biol. 2005, 171:663-673.
84. Reis-Filho J.S., Simpson P.T., Turner N.C., Lambros M.B., Jones C., Mackay A., Grigoriadis A., Sarrio D., Savage K., Dexter T., Iravani M., Fenwick K., Weber B., Hardisson D., Schmitt F.C., Palacios J., Lakhani S.R., Ashworth A. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin. Cancer Res. 2006, 12:6652-6662.
85. Bai A., Meetze K., Vo N.Y., Kollipara S., Mazsa E.K., Winston W.M., Weiler S., Poling L.L., Chen T., Ismail N.S., Jiang J., Lerner L., Gyuris J., Weng Z. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010, 70:7630-7639.
86. Nord H., Segersten U., Sandgren J., Wester K., Busch C., Menzel U., Komorowski J., Dumanski J.P., Malmström P.U., Díaz de Ståhl T. Focal amplifications are associated with high-grade and recurrences in stage Ta bladder carcinoma. Int. J. Cancer 2009, 126:1390-1402.
87. Gorringe K.L., Jacobs S., Thompson E.R., Sridhar A., Qiu W., Choong D.Y., Campbell I.G. High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Clin. Cancer Res. 2007, 13:4731-4739.
88. Missiaglia E., Selfe J., Hamdi M., Williamson D., Schaaf G., Fang C., Koster J., Summersgill B., Messahel B., Versteeg R., Pritchard-Jones K., Kool M., Shipley J. Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer 2009, 48:455-467.
89. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D., Ballinger D.G., Struewing J.P., Morrison J., Field H., Luben R., Wareham N., Ahmed S., Healey C.S., Bowman R., Meyer K.B., Haiman C.A., Kolonel L.K., Henderson B.E., Le Marchand L., Brennan P., Sangrajrang S., Gaborieau V., Odefrey F., Shen C.Y., Wu P.E., Wang H.C., Eccles D., Evans D.G., Peto J., Fletcher O., Johnson N., Seal S., Stratton M.R., Rahman N., Chenevix-Trench G., Bojesen S.E., Nordestgaard B.G., Axelsson C.K., Garcia-Closas M., Brinton L., Chanock S., Lissowska J., Peplonska B., Nevanlinna H., Fagerholm R., Eerola H., Kang D., Yoo K.Y., Noh D.Y., Ahn S.H., Hunter D.J., Hankinson S.E., Cox D.G., Hall P., Wedren S., Liu J., Low Y.L., Bogdanova N., Schurmann P., Dork T., Tollenaar R.A., Jacobi C.E., Devilee P., Klijn J.G., Sigurdson A.J., Doody M.M., Alexander B.H., Zhang J., Cox A., Brock I.W., MacPherson G., Reed M.W., Couch F.J., Goode E.L., Olson J.E., Meijers-Heijboer H., van den Ouweland A., Uitterlinden A., Rivadeneira F., Milne R.L., Ribas G., Gonzalez-Neira A., Benitez J., Hopper J.L., McCredie M., Southey M., Giles G.G., Schroen C., Justenhoven C., Brauch H., Hamann U., Ko Y.D., Spurdle A.B., Beesley J., Chen X., Mannermaa A., Kosma V.M., Kataja V., Hartikainen J., Day N.E., Cox D.R., Ponder B.A. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
90. Hunter D.J., Kraft P., Jacobs K.B., Cox D.G., Yeager M., Hankinson S.E., Wacholder S., Wang Z., Welch R., Hutchinson A., Wang J., Yu K., Chatterjee N., Orr N., Willett W.C., Colditz G.A., Ziegler R.G., Berg C.D., Buys S.S., McCarty C.A., Feigelson H.S., Calle E.E., Thun M.J., Hayes R.B., Tucker M., Gerhard D.S., Fraumeni J.F., Hoover R.N., Thomas G., Chanock S.J. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 2007, 39:870-874.
91. Carroll J.S., Meyer C.A., Song J., Li W., Geistlinger T.R., Eeckhoute J., Brodsky A.S., Keeton E.K., Fertuck K.C., Hall G.F., Wang Q., Bekiranov S., Sementchenko V., Fox E.A., Silver P.A., Gingeras T.R., Liu X.S., Brown M. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 2006, 38:1289-1297.
92. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
93. Naski M.C., Wang Q., Xu J., Ornitz D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nat. Genet. 1996, 13:233-237.
94. Yu K., Xu J., Liu Z., Sosic D., Shao J., Olson E.N., Towler D.A., Ornitz D.M. Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 2003, 130:3063-3074.
95. Wilkie A.O. Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev. 2005, 16:187-203.
96. Hernandez S., de Muga S., Agell L., Juanpere N., Esgueva R., Lorente J.A., Mojal S., Serrano S., Lloreta J. FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod. Pathol. 2009, 22:848-856.
97. Dutt A., Salvesen H.B., Chen T.H., Ramos A.H., Onofrio R.C., Hatton C., Nicoletti R., Winckler W., Grewal R., Hanna M., Wyhs N., Ziaugra L., Richter D.J., Trovik J., Engelsen I.B., Stefansson I.M., Fennell T., Cibulskis K., Zody M.C., Akslen L.A., Gabriel S., Wong K.K., Sellers W.R., Meyerson M., Greulich H. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8713-8717.
98. Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A., Kuehl W.M., Bergsagel P.L. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001, 97:729-736.
99. Chou A., Dekker N., Jordan R.C. Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009, 107:535-541.
100. Davies H., Hunter C., Smith R., Stephens P., Greenman C., Bignell G., Teague J., Butler A., Edkins S., Stevens C., Parker A., O'Meara S., Avis T., Barthorpe S., Brackenbury L., Buck G., Clements J., Cole J., Dicks E., Edwards K., Forbes S., Gorton M., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jones D., Kosmidou V., Laman R., Lugg R., Menzies A., Perry J., Petty R., Raine K., Shepherd R., Small A., Solomon H., Stephens Y., Tofts C., Varian J., Webb A., West S., Widaa S., Yates A., Brasseur F., Cooper C.S., Flanagan A.M., Green A., Knowles M., Leung S.Y., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B.T., Yuen S.T., Lakhani S.R., Easton D.F., Weber B.L., Goldstraw P., Nicholson A.G., Wooster R., Stratton M.R., Futreal P.A. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res. 2005, 65:7591-7595.
101. Pollock P.M., Gartside M.G., Dejeza L.C., Powell M.A., Mallon M.A., Davies H., Mohammadi M., Futreal P.A., Stratton M.R., Trent J.M., Goodfellow P.J. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007, 26:7158-7162.
102. Cho J.Y., Guo C., Torello M., Lunstrum G.P., Iwata T., Deng C., Horton W.A. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:609-614.
103. Gartside M.G., Chen H., Ibrahimi O.A., Byron S.A., Curtis A.V., Wellens C.L., Bengston A., Yudt L.M., Eliseenkova A.V., Ma J., Curtin J.A., Hyder P., Harper U.L., Riedesel E., Mann G.J., Trent J.M., Bastian B.C., Meltzer P.S., Mohammadi M., Pollock P.M. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 2009, 7:41-54.
104. Cappellen D., De Oliveira C., Ricol D., de Medina S., Bourdin J., Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 1999, 23:18-20.
105. Cheng L., Zhang S., Davidson D.D., MacLennan G.T., Koch M.O., Montironi R., Lopez-Beltran A. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol. 2009, 5:843-857.
106. di Martino E., L'Hote C., Kennedy W., Tomlinson D.C., Knowles M.A. Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene 2009, 28:4306-4316.
107. Munro N.P., Knowles M.A. Fibroblast growth factors and their receptors in transitional cell carcinoma. J. Urol. 2003, 169:675-682.
108. Knowles M.A. Molecular pathogenesis of bladder cancer. Int. J. Clin. Oncol. 2008, 13:287-297.
109. Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., Miller W.T., Mohammadi M. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell 2007, 27:717-730.
110. Tomlinson D.C., Hurst C.D., Knowles M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene 2007, 26:5889-5899.
111. Martinez-Torrecuadrada J. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin. Cancer Res. 2005, 11:6280-6290.
112. Miyake M., Ishii M., Koyama N., Kawashima K., Kodama T., Anai S., Fujimoto K., Hirao Y., Sugano K. 1-Tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyr ido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J. Pharmacol. Exp. Ther. 2010, 332:795-802.
113. Bernard-Pierrot I., Brams A., Dunois-Larde C., Caillault A., Diez de Medina S.G., Cappellen D., Graff G., Thiery J.P., Chopin D., Ricol D., Radvanyi F. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis 2006, 27:740-747.
114. Martinez-Torrecuadrada J.L., Cheung L.H., Lopez-Serra P., Barderas R., Canamero M., Ferreiro S., Rosenblum M.G., Casal J.I. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol. Cancer Ther. 2008, 7:862-873.
115. Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A., Gasc J.M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P., Radvanyi F. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. Hum. Mol. Genet. 2005, 14:1153-1160.
116. Ahmad I., Singh L.B., Foth M., Morris C.A., Taketo M.M., Wu X.R., Leung H.Y., Sansom O.J., Iwata T. K-Ras and beta-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Dis. Model. Mech. 2011, 4:548-555.
117. Rosty C. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol. Cancer 2005, 4:15.
118. Goriely A. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat. Genet. 2009, 41:1247-1252.
119. Zhang Y., Hiraishi Y., Wang H., Sumi K.S., Hayashido Y., Toratani S., Kan M., Sato J.D., Okamoto T. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int. J. Cancer 2005, 117:166-168.
120. Aubertin J., Tourpin S., Janot F., Ahomadegbe J.C., Radvanyi F. Analysis of fibroblast growth factor receptor 3 G697C mutation in oral squamous cell carcinomas. Int. J. Cancer 2007, 120:2058-2059.
121. Hafner C., van Oers J.M., Vogt T., Landthaler M., Stoehr R., Blaszyk H., Hofstaedter F., Zwarthoff E.C., Hartmann A. Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J. Clin. Invest. 2006, 116:2201-2207.
122. Mandinova A., Kolev V., Neel V., Hu B., Stonely W., Lieb J., Wu X., Colli C., Han R., Pazin M.J., Ostano P., Dummer R., Brissette J.L., Dotto G.P. A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. J. Clin. Invest. 2009, 119:3127-3137.
123. Jebar A.H., Hurst C.D., Tomlinson D.C., Johnston C., Taylor C.F., Knowles M.A. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005, 24:5218-5225.
124. Byron S.A., Gartside M.G., Wellens C.L., Mallon M.A., Keenan J.B., Powell M.A., Goodfellow P.J., Pollock P.M. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res. 2008, 68:6902-6907.
125. Yu K., Herr A.B., Waksman G., Ornitz D.M. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14536-14541.
126. Ornitz D.M., Marie P.J. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 2002, 16:1446-1465.
127. Taylor J.G., Cheuk A.T., Tsang P.S., Chung J.Y., Song Y.K., Desai K., Yu Y., Chen Q.R., Shah K., Youngblood V., Fang J., Kim S.Y., Yeung C., Helman L.J., Mendoza A., Ngo V., Staudt L.M., Wei J.S., Khanna C., Catchpoole D., Qualman S.J., Hewitt S.M., Merlino G., Chanock S.J., Khan J. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 2009, 119:3395-3407.
128. Khan J., Wei J.S., Ringner M., Saal L.H., Ladanyi M., Westermann F., Berthold F., Schwab M., Antonescu C.R., Peterson C., Meltzer P.S. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat. Med. 2001, 7:673-679.
129. Thussbas C., Nahrig J., Streit S., Bange J., Kriner M., Kates R., Ulm K., Kiechle M., Hoefler H., Ullrich A., Harbeck N. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J. Clin. Oncol. 2006, 24:3747-3755.
130. Bange J., Prechtl D., Cheburkin Y., Specht K., Harbeck N., Schmitt M., Knyazeva T., Muller S., Gartner S., Sures I., Wang H., Imyanitov E., Haring H.U., Knayzev P., Iacobelli S., Hofler H., Ullrich A. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002, 62:840-847.
131. Cha J.Y., Lambert Q.T., Reuther G.W., Der C.J. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol. Cancer Res. 2008, 6:435-445.
132. Itoh H., Hattori Y., Sakamoto H., Ishii H., Kishi T., Sasaki H., Yoshida T., Koono M., Sugimura T., Terada M. Preferential alternative splicing in cancer generates a K-sam messenger RNA with higher transforming activity. Cancer Res. 1994, 54:3237-3241.
133. Ezzat S., Zheng L., Zhu X.F., Wu G.E., Asa S.L. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Invest. 2002, 109:69-78.
134. Savagner P., Valles A.M., Jouanneau J., Yamada K.M., Thiery J.P. Alternative splicing in fibroblast growth factor receptor 2 is associated with induced epithelial-mesenchymal transition in rat bladder carcinoma cells. Mol. Biol. Cell 1994, 5:851-862.
135. Yan G., Fukabori Y., McBride G., Nikolaropolous S., McKeehan W.L. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol. Cell. Biol. 1993, 13:4513-4522.
136. Oltean S., Sorg B.S., Albrecht T., Bonano V.I., Brazas R.M., Dewhirst M.W., Garcia-Blanco M.A. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14116-14121.
137. Haugsten E.M., Sorensen V., Brech A., Olsnes S., Wesche J. Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors. J. Cell Sci. 2005, 118:3869-3881.
138. Mosesson Y., Mills G.B., Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat. Rev. Cancer 2008, 8:835-850.
139. Haglund K., Rusten T.E., Stenmark H. Aberrant receptor signaling and trafficking as mechanisms in oncogenesis. Crit. Rev. Oncog. 2007, 13:39-74.
140. Abella J.V., Park M. Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E973-E984.
141. Zisman-Rozen S., Fink D., Ben-Izhak O., Fuchs Y., Brodski A., Kraus M.H., Bejar J., Ron D. Downregulation of Sef, an inhibitor of receptor tyrosine kinase signaling, is common to a variety of human carcinomas. Oncogene 2007, 26:6093-6098.
142. Darby S., Murphy T., Thomas H., Robson C.N., Leung H.Y., Mathers M.E., Gnanapragasam V.J. Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease. Br. J. Cancer 2009, 101:1891-1899.
143. Darby S., Sahadevan K., Khan M.M., Robson C.N., Leung H.Y., Gnanapragasam V.J. Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene 2006, 25:4122-4127.
144. Wang Y., Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat. Med. 1997, 3:887-893.
145. Birrer M.J., Johnson M.E., Hao K., Wong K.K., Park D.C., Bell A., Welch W.R., Berkowitz R.S., Mok S.C. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J. Clin. Oncol. 2007, 25:2281-2287.
146. Mattila M.M., Harkonen P.L. Role of fibroblast growth factor 8 in growth and progression of hormonal cancer. Cytokine Growth Factor Rev. 2007, 18:257-266.
147. Marsh S.K., Bansal G.S., Zammit C., Barnard R., Coope R., Roberts-Clarke D., Gomm J.J., Coombes R.C., Johnston C.L. Increased expression of fibroblast growth factor 8 in human breast cancer. Oncogene 1999, 18:1053-1060.
148. Theodorou V., Kimm M.A., Boer M., Wessels L., Theelen W., Jonkers J., Hilkens J. MMTV insertional mutagenesis identifies genes, gene families and pathways involved in mammary cancer. Nat. Genet. 2007, 39:759-769.
149. Daphna-Iken D., Shankar D.B., Lawshe A., Ornitz D.M., Shackleford G.M., MacArthur C.A. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia. Oncogene 1998, 17:2711-2717.
150. MacArthur C.A., Shankar D.B., Shackleford G.M. Fgf-8, activated by proviral insertion, cooperates with the Wnt-1 transgene in murine mammary tumorigenesis. J. Virol. 1995, 69:2501-2507.
151. Song Z., Wu X., Powell W.C., Cardiff R.D., Cohen M.B., Tin R.T., Matusik R.J., Miller G.J., Roy-Burman P. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002, 62:5096-5105.
152. Valta M.P., Tuomela J., Bjartell A., Valve E., Vaananen H.K., Harkonen P. FGF-8 is involved in bone metastasis of prostate cancer. Int. J. Cancer 2008, 123:22-31.
153. Desnoyers L.R., Pai R., Ferrando R.E., Hotzel K., Le T., Ross J., Carano R., D'Souza A., Qing J., Mohtashemi I., Ashkenazi A., French D.M. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008, 27:85-97.
154. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., Pham T.A., Dillard-Telm L., Tsai S.P., Stephan J.P., Stinson J., Stewart T., French D.M. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 2002, 160:2295-2307.
155. Memarzadeh S., Xin L., Mulholland D.J., Mansukhani A., Wu H., Teitell M.A., Witte O.N. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell 2007, 12:572-585.
156. Abdel-Rahman W.M., Kalinina J., Shoman S., Eissa S., Ollikainen M., Elomaa O., Eliseenkova A.V., Butzow R., Mohammadi M., Peltomaki P. Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin. Hum. Mutat. 2008, 29:390-397.
157. Whitelock J.M., Murdoch A.D., Iozzo R.V., Underwood P.A. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J. Biol. Chem. 1996, 271:10079-10086.
158. Vlodavsky I., Elkin M., Abboud-Jarrous G., Levi-Adam F., Fuks L., Shafat I., Ilan N. Heparanase: one molecule with multiple functions in cancer progression. Connect. Tissue Res. 2008, 49:207-210.
159. Marshall M.E., Hinz T.K., Kono S.A., Singleton K.R., Bichon B., Ware K.E., Marek L., Frederick B.A., Raben D., Heasley L.E. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 2011, 17:5016-5025.
160. Amann T., Bataille F., Spruss T., Dettmer K., Wild P., Liedtke C., Muhlbauer M., Kiefer P., Oefner P.J., Trautwein C., Bosserhoff A.K., Hellerbrand C. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am. J. Pathol. 2010, 176:1433-1442.
161. Diez de Medina S.G., Chopin D., El Marjou A., Delouvee A., LaRochelle W.J., Hoznek A., Abbou C., Aaronson S.A., Thiery J.P., Radvanyi F. Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene 1997, 14:323-330.
162. Naimi B., Latil A., Fournier G., Mangin P., Cussenot O., Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002, 52:245-252.
163. Zhang Y., Wang H., Toratani S., Sato J.D., Kan M., McKeehan W.L., Okamoto T. Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11336-11340.
164. Grose R., Fantl V., Werner S., Chioni A.M., Jarosz M., Rudling R., Cross B., Hart I.R., Dickson C. The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J. 2007, 26:1268-1278.
165. Ricol D., Cappellen D., El Marjou A., Gil-Diez-de-Medina S., Girault J.M., Yoshida T., Ferry G., Tucker G., Poupon M.F., Chopin D., Thiery J.P., Radvanyi F. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999, 18:7234-7243.
166. Giri D., Ropiquet F., Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. 1999, 5:1063-1071.
167. Nomura S., Yoshitomi H., Takano S., Shida T., Kobayashi S., Ohtsuka M., Kimura F., Shimizu H., Yoshidome H., Kato A., Miyazaki M. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br. J. Cancer 2008, 99:305-313.
168. Toyokawa T., Yashiro M., Hirakawa K. Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma. Oncol. Rep. 2009, 21:875-880.
169. Cho K., Ishiwata T., Uchida E., Nakazawa N., Korc M., Naito Z., Tajiri T. Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer. Am. J. Pathol. 2007, 170:1964-1974.
170. Koziczak M., Holbro T., Hynes N.E. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 2004, 23:3501-3508.
171. Mohammadi M. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998, 17:5896-5904.
172. Sarker D., Molife R., Evans T.R., Hardie M., Marriott C., Butzberger-Zimmerli P., Morrison R., Fox J.A., Heise C., Louie S., Aziz N., Garzon F., Michelson G., Judson I.R., Jadayel D., Braendle E., de Bono J.S. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors. Clin. Cancer Res. 2008, 14:2075-2081.
173. Machida S., Saga Y., Takei Y., Mizuno I., Takayama T., Kohno T., Konno R., Ohwada M., Suzuki M. Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). Int. J. Cancer 2005, 114:224-229.
174. Chen J., Lee B.H., Williams I.R., Kutok J.L., Mitsiades C.S., Duclos N., Cohen S., Adelsperger J., Okabe R., Coburn A., Moore S., Huntly B.J., Fabbro D., Anderson K.C., Griffin J.D., Gilliland D.G. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005, 24:8259-8267.
175. Matsui J., Yamamoto Y., Funahashi Y., Tsuruoka A., Watanabe T., Wakabayashi T., Uenaka T., Asada M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 2008, 122:664-671.
176. Hilberg F., Roth G.J., Krssak M., Kautschitsch S., Sommergruber W., Tontsch-Grunt U., Garin-Chesa P., Bader G., Zoephel A., Quant J., Heckel A., Rettig W.J. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008, 68:4774-4782.
177. AstraZeneca http://www.astrazeneca-annualreports.com/2009/additional_information/index.html.
178. Novartis http://www.novartisoncology.com/research-innovation/pipeline/bgj398.jsp?usertrack.filter_applied=true&NovaId=2935376892995015019.
179. Pardo O.E., Latigo J., Jeffery R.E., Nye E., Poulsom R., Spencer-Dene B., Lemoine N.R., Stamp G.W., Aboagye E.O., Seckl M.J. The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res. 2009, 69:8645-8651.
180. Five-Prime http://fiveprime.com/index.php?option=com_content&view=article&id=222&Itemid=153.
181. Spielberger R. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 2004, 351:2590-2598.